Kymera Therapeutics KYMR
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Kymera Therapeutics (KYMR) Business Model and Operations Summary
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Key Insights
Kymera Therapeutics (KYMR) Core Market Data and Business Metrics
Latest Closing Price
$25.235Market Cap
$1.65 BillionPrice-Earnings Ratio
-8.47Total Outstanding Shares
64.94 Million SharesTotal Employees
188Dividend
No dividendIPO Date
August 21, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
500 North Beacon Street, 4th Floor, Watertown, MA, 02472
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $10.27 Million |
| Net Cash Flow | $10.27 Million |
| Net Cash Flow From Investing Activities, Continuing | $-404.08 Million |
| Net Cash Flow From Investing Activities | $-404.08 Million |
| Net Cash Flow From Operating Activities, Continuing | $-194.50 Million |
| Net Cash Flow From Operating Activities | $-194.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Earnings Per Share | $-2.98 |
| Net Income/Loss Available To Common Stockholders, Basic | $-223.86 Million |
| Net Income/Loss Attributable To Parent | $-223.86 Million |
| Net Income/Loss | $-223.86 Million |
| Revenues | $47.07 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-224.79 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-933,000 |
| Comprehensive Income/Loss Attributable To Parent | $-224.79 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $417.31 Million |
| Current Liabilities | $67.77 Million |
| Assets | $978.03 Million |
| Liabilities And Equity | $978.03 Million |
| Liabilities | $142.42 Million |
| Accounts Payable | $5.99 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||